The first-line metastatic Melanoma market is currently dominated by immune checkpoint inhibitors—BMS' Opdivo + Yervoy, Opdualag, Opdivo,...

Focus - Melanoma Indication Malignant melanoma is a complex, multifactorial disease, which is responsible for up to 75% of skin...